The United States Food and Drug Administration has announced its approval of the first genetic therapy treatment for sickle cell disease. The drug exagamglogene autotemcel, commercially know as ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine A new chapter is unfolding for patients with sickle cell ...
(MEMPHIS, Tenn. – October 12, 2022) Scientists at St. Jude Children’s Research Hospital have shown how a protein responsible for adapting to low oxygen conditions (hypoxia), causes increased ...
(MEMPHIS, Tenn. – July 03, 2023) Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia. These two common life-threatening anemias afflict ...
The Food and Drug Administration (FDA) approved the gene therapy Casgevy in December, which uses CRISPR/Cas9 genome editing technology to treat sickle-cell disease (SCD) in patients twelve years and ...
Scientists at St. Jude Children’s Research Hospital and other colleagues say they have shown how a protein responsible for adapting to low oxygen conditions (hypoxia), causes increased expression of ...
Scientists at St. Jude Children's Research Hospital have shown how a protein responsible for adapting to low oxygen conditions (hypoxia), causes increased expression of fetal hemoglobin (HbF) in ...
It was only 11 years ago that scientists Jennifer Doudna and Emmanuelle Charpentier first described a new way to edit genes, called CRISPR, in a scientific paper. The discovery is so game-changing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results